Announced
Completed
Synopsis
Acelyrin, a biotechnology company, completed the acquisition of ValenzaBio, a drug startup. Financial terms were not disclosed. "ACELYRIN was founded a little over two years ago to identify, acquire, and accelerate the development and delivery of therapies with the potential to provide clinically meaningful, differentiated benefits to patients based on the science of the targets or characteristics of the molecules. The previously shared Phase 2 psoriatic arthritis data support our hypothesis that the characteristics of izokibep can lead to differentiated patient outcomes relative to current treatment options, and the results reported separately today for hidradenitis suppurativa now offer data in a second indication that further support that hypothesis. The acquisition of ValenzaBio adds additional programs to our portfolio, such as lonigutamab, which we believe similarly have the potential to offer clinically meaningful, differentiated benefits relative to current treatment options," Shao-Lee Lin, ACELYRIN Founder and CEO.
Principals
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.